Publications by authors named "Rune Boas"
Patients with non-ischemic systolic heart failure (HF) have increased risk of sudden cardiovascular death (SCD). The initiation and substrate for ventricular arrhythmias remains poorly understood. Our purpose was to describe the relationship between cardiac magnetic resonance (CMR) late gadolinium enhancement (LGE) and Holter recorded ventricular arrhythmic activity.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how periodic repolarization dynamics (PRD) can identify nonischemic cardiomyopathy patients who might benefit from getting a cardioverter-defibrillator (ICD) implanted as a preventive measure against sudden cardiac events.
- A post hoc analysis of the DANISH trial included patients with severe heart function issues (LVEF ≤35% and high NT-proBNP levels) to see how baseline PRD, measured using 24-hour Holter monitors, related to their mortality.
- Results showed that higher PRD was linked to higher mortality in patients not receiving ICDs, while there was no significant link in those with ICDs, suggesting that PRD could help target patients who would benefit most from ICD therapy
Article Synopsis
- * Researchers analyzed data from 850 patients with severe heart failure, monitoring their heart for 24 hours to find indicators like non-sustained ventricular tachycardia (NSVT) and the burden of premature ventricular contractions (PVCs).
- * Results showed that while both NSVT and high PVC burden were linked to higher overall mortality and cardiovascular death, they did not help in predicting which patients would benefit from ICD implantation.
Article Synopsis
- Atrial fibrillation (AF) and excessive supraventricular ectopic activity (ESVEA) in patients with nonischemic heart failure (HF) were linked to higher mortality rates, including all-cause and cardiovascular deaths.
- In a study of 850 patients, 22% had AF and 10% had ESVEA, with both conditions leading to significantly increased risks of death over nearly five years of follow-up.
- The implantation of a prophylactic implantable cardioverter defibrillator (ICD) did not show any improvement in outcomes for patients with AF or ESVEA, indicating that management strategies may need re-evaluation.